Category not found


Fast Development and Production

The iBio Technology dramatically speeds up drug development and production.

Accelerated production and development is possible because plants are not genetically modified. By using non-GMO plants as manufacturing platform, the iBio Technology process eliminates the months or years needed by technologies using mammalian cells to find a high-producing stable cell clone that can be expanded into the trillions of daughter cells required for manufacturing useful amounts of a drug.


Produce Novel Protein Product at Factory Scale, Fast

Using the iBio Technology, a novel protein product can be manufactured for commercial use in less than a month.

Once a desired gene is cloned into the iBio Technology vectors, it is introduced into the leaves of the plants by automated vacuum infiltration technology. Over the next 4-7 days, the vector inserts the new gene into the nucleus of the plant cell and "hijacks" the cellular protein synthesis machinery to produce the new heterologous protein.


building bim2

Flexible Technology Allows for Agile Production

Production of multiple proteins simultaneously is made a reality by the iBio Technology.

Since the growth of plants and introduction of the iBio Technology vectors is the same regardless of the desired product, a facility using the iBio Technology system can easily produce multiple proteins in the same facility without physical reconfiguration.




Making Biopharmaceuticals From Plants

The iBio Technology is a Unique Plant-Based Platform that Accelerates the Development and Manufacturing of High Levels of Target Protein.

  • Early stage feasibility - candidate molecules in weeks
  • Seamless scale-up - rapid process development
  • Ready for clinical trials - bulk drug substance in months

The Plant-Based Process

  1. iBio scientists engineer vectors containing the target sequence within a viral replicon.
  2. The vector is transferred to an Agrobacterium host that efficiently introduces target DNA to the plant cell nucleus.
  3. The viral replicon directs the production of large amounts of target-specific messenger RNA in plant cells, which is translated into protein by the plant’s own machinery for several days.
  4. Once the plants have been infiltrated with agrobacteria, the viral sequences of the launch vectors, along with the cloned target sequences, are massively amplified through the action of virally encoded enzymes. Translation of these recombinant viral vector mRNAs can result in the accumulation of gram quantities of target protein per kilogram of fresh plant tissue in less than a week.
  5. The plants accumulate high levels of target protein in their leaf tissue. This expression of recombinant protein is termed “transient” expression because the target gene sequence is expressed as protein for a fixed period of time, and the foreign genes are not incorporated into the plant chromosomes. No transgenic plants or seeds are formed.
  6. The plant biomass is harvested, homogenized, and clarified to produce an extract containing the protein of interest. Proteins are further purified as required using conventional separation and chromatography steps widely used in the biopharmaceutical industry.

Market Data copyright © 2018 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.